The Global mTOR Inhibitor Torin1 is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylases Inhibitors, in Suppressing Neuroendocrine Tumors Cell Proliferation

#220

Introduction: Torin1, a new mTOR inhibitor that globally inhibits both mTORC1 and mTORC2, seems to impair cell growth and proliferation to a greater degree than rapamycin; its effects in NET cells are unknown.

Aim(s): To examine for the first time the potential effects of Torin1 v. everolimus, alone or in combination with two different HDACi agents in NETs cells.

Materials and methods: Two NETs cell lines (human pancreatic carcinoid cell line (BON1) and rat insulinoma cell line (RIN)), as well as cells extracted from human NETs after surgical excision, were treated with everolimus, Torin1 and HDACi, in order to study their anti-proliferative effects, as well as the efficacy of the combination of everolimus with HDACi v. Torin.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Grozinsky-Glasberg S, Rubinfeld H, Cohen O, Greif F, Kammer A,

Keywords: Torin1, RAD001, NETs, antiproliferation, Akt, mTOR, HDACi,

To read the full abstract, please log into your ENETS Member account.